PROSTATIC ENLARGMENT& LUTS

Slides:



Advertisements
Similar presentations
Advances in the Management of BPH
Advertisements

Benign Prostatic Hyperplasia
NICE LUTS Clinical Guideline 2010
BPH Diagnosis and Medical Treatment
Phase 2 Patrick King The Peer Teaching Society is not liable for false or misleading information…
Supervised by: Dr- Al Traifi. Why LUTS? What are the symptoms? Common causes? Patient work up Details of the Common etiology BPH.
Benign Prostatic Hyperplasia
MODULE 5 1/23 Case 9: Pierre. MODULE 5 Case 9: Pierre 2/23 Patient History  Pierre is 65 years of age who has suffered with benign prostatic hyperplasia.
BPH, Inflammatory diseases of prostate As. Prof. Lukáš Bittner M.D., FEBU Urologická klinika 3. LF UK a FNKV.
Benign Prostatic Hyperplasia Dr.Bandar Al Hubaishy Urology Department KAUH.
The Aging Prostate: Presentation, Diagnosis & Management Professor Riyadh F. Talic, MD Professor of Urology & Andrology College of Medicine, King Khalid.
BPH – From Diagnosis To Treatment Strategies in GP Practice
Thursday School December 11, 2014 Richard Hoffman, MD, MPH.
Benign Prostatic Hypertrophy
BPH Riccel and Von. Medical Therapy 5a-Reductase inhibitors Finasteride – Blocks the conversion of testosterone to dihydrotestosterone This drug affects.
Lower Urinary Tract Symptoms in Men
All About the Prostate For Intelligent Internists
Prostatic neoplasms / cancer Behavioral Objectives – Describe etiology, pathophysiology, clinical manifestations, nursing management and patient education.
Benign Prostatic Hypertrophy Hyperplasia Enlargement
Lower Urinary Tract Symptoms (LUTS) in men Kamal Patel GPST2.
2008. Causes of symptoms  Hyperplasia of epithelial and stromal components of prostate  Progressive obstruction of urinary outflow  Increased activity.
Prostate.
Benign Prostatic Hyperplasia
Introduction to Urology
Dr Charles Chabert Urinary Symptoms &GreenLight Laser Prostatectomy.
Benign Prostatic Hyperplasia. Objectives Upon Completion of this CME activity, the learner will be able to: – Understanding the current medical management.
Neoplasms of the Prostate Gland
Lower Urinary Tract Symptoms (LUTS)
LUTS Shawket Alkhayal Consultant Urological Surgeon Benenden Hospital Tunbridge Wells Nuffield Hospital.
Benign Prostatic Hyperplasia
Adult Medical-Surgical Nursing
Urology Update Sanofi- Aventis
Check your knowledge in… BHP/LUTS. 5-alpha-reductase inhibitors in the treatment of BPH Induce a significant decrease of libido 2 - Increase maximum.
Asim Pasha.  Common condition seen in older men  Risk factors  1-age:  Around 50% of 50-year-old men will have evidence of BPH and 30% will have symptoms.
Benign Prostatic Hyperplasia (BPH)
Benign prostateic hyperplasia
Mark Lynch Clinical Lead Urology, Croydon University Hospital Consultant, St George’s Hospital
BPH.
URETHRAL STRICTURES BY PATTI HAMILTON. What is a urethral stricture? A urethral stricture is a narrowing in any part of the urethra – the tube that drains.
Figure 1. Gross specimen of prostate gland.. Figure 2. Microscopic effects of BPH.
The GOLIATH Study ..
Benign prostatic hyperplasia
Urethral stricture. *May be congenital or acquired. *Acquired urethral sricture is common in men but rare in women. Aetiology 1. congenital 2. Traumatic.
Genitourinary Blueprint
DR. MOHAMMED ALTURKI COSULTANT UROLOGIST. Evaluation of the Urologic Patient The urologist has the ability to make the initial evaluation and diagnosis.
Benign Prostatic Hyperplasia (BPH) and Prostatitis Matthew Lane, PharmD, BCPS Associate Professor University of Kentucky.
A 50 year old diabetic female presented with burning micturition associated with urinary frequency & suprapubic pain.
Carcinoma of Bladder & Prostate BPH
Benign Prostate Hypertrophy (BPH). Introduction Benign prostatic hyperplasia refers to nonmalignant growth of prostate. – age-related phenomenon in nearly.
BENIGN PROSTATIC HYPERPLASIA Brian Kim, PGY3. A Case…  Mr. X is a 58y/o AAM presents to your clinic complaining of hesitancy, frequency, and nocturia.
Department of Urology, Guangzhou First Municipal People’s Hospital, Guangzhou Medical College, Guangzhou, China Rubiao Ou, Meng You, Ping Tang, Hui Chen,
Benign prostate hyperplasia Div. of Urology, Dept. Surgery Medical Faculty, University of Sumatera Utara.
Benign Prostatic Hyperplasia Rajan Narula Senior Staff Specialist The Townsville Hospital.
Disease review Benigh Prostatic Hyperplasia GU PK19 조 51 번 오민주.
Benign Prostatic Hyperplasia (BPH). Prostate gland : is a fbromuscular and glandular organ lying Just inferior to the bladder. According to Mcneal, the.
Canadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases
Signs and Symptoms of Urinary Tract Disorders
BENIGN PROSTATIC HYPERPLASIA (Module 2 of Renal/Prostate Disease)
Benign Prostatic Hyperplasia: Trends in Medical Management
Group Issues Guidelines on Prostate Cancer Screening . . .
Benign prostatic hyperplasia
BLADDER OUTLET OBSTRUCTION (B. O. O. ) BLADDER OUT FLOW OBSTRUTION (B
Benign prostatic hyperplasia
PITFALLS IN OPEN PROSTATIC SURGERY
BENIGN PROSTATIC HYPERPLASIA
Endocrinology: Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Medical-Surgical Nursing: Concepts & Practice
Functional disorders of the lower urinary tract
Presentation transcript:

PROSTATIC ENLARGMENT& LUTS

BPH is a histological diagnosis & doesn’t necessarily implies benign prostatic enlargement (BPE)or symptoms. Bladder outlet obstruction(B.O.O.) Lower yrinary tract symptoms( LUTS) It is not a diagnostic term &indicate all lower urinary tract symptoms that results from either bladder dysfunction or response of the bladder to a pathology in the prostate or urethra that causes bladder outlet obstruction.this symptom complex was previously referred to as prostatism

BENIGN PROSTATIC HYPERPLASIA BPH BPH is the most common benign tumor in men, and its incidence ( histological and clinical ) is age related. Etiology The etiology of BPH is not completely understood, but it seems to be multifactorial and endocrine controlled.

Both stromal &epithelial components can produce hyperplastic nodules causing BPH. There is a positive correlation between levels of free testosterone , estrogen levels &volume of BPH. No studies to date have been able to domonstrate the increased estrogen receptors level in human BPH.

Pathology BPH develops in the transitional zone as a hyperplastic process with nodules formation in the stroma (collagen & smooth muscles)&epithelium, this affects the potential responsiveness to medical treatment. As BPH nodules in the transition zone enlarge, they compress the outer zones of the prostate, resulting in the formation of a so-called surgical capsule.

This boundary separates the transition zone from the peripheral zone and serves as a cleavage plane for open enucleation of the prostate during open simple prostatectomies performed for BPH.

Pathophysiology

Pathophysiology Symptoms of BPH are related to: 1. Obstructive effect of the prostate ( mechanical & dynamic). 2. The response of the bladder to outlet resistance. ( causes detrusor instability ,low bladder compliance ,trabeculation & diverticulae formation in the wall of the bladder & ultimately causes bladder decompensation).

Clinical Findings Urinary hesitancy. Decreased force of urination. A - OBSTRUCTIVE urinary symptoms : Urinary hesitancy. Decreased force of urination. Straining. Intermittency. Postvoid dribbling. Incomplete emptying.

B – Irritative urinary symptoms Frequency. Nocturia . Urgency. Urge Incontinence. C – Associated symptoms. Dysuria , hematuria , loin or suprapubic pain ,history of STD or urethral trauma , neurological symptoms , erectile functions ,retention of urine .

SIGNS General Examination . Abdominal Examination. DRE. Focused Neurological Examination.

INVESTIGATIONS Routine G.U.E KFT. PSA. IPSS. Optional U/S. IVU. UDS. CYSTOSCOPY.

Differential Diagnosis Urethral Stricture. Bladder Neck Contracture. Bladder Stone. Ca. Prostate. Neuropathic bladder.

Treatment A. WATCHFUL WAITING. B. MEDICAL THERAPY. C. MINIMALLY INVASIVE THERAPY. D. CONVENTIONAL SURGICAL THERAPY

B. MEDICAL THERAPY. 1-Alpha-blockers

Finasteride 5 mg daily Dutasteride 0.5 mg daily 2- 5-alpha-reductase inhibitors Finasteride 5 mg daily Dutasteride 0.5 mg daily Reduce the incidence of AUR. Reduce the need for surgical therapy. Reduce blood loss after Prostatic surgery.

3. Combination therapy 4. Phytotherapy : Several plant extractshave been popularized, including the saw palmetto berry, (Serenoa repens) the bark of Pygeum africanum.

C. MINIMALLY INVASIVE THERAPY.

ENDOSCOPIC TURP TUIP OPEN TVP RPP SURGICAL THERAPY

Indications of surgery 1- failure of medical therapy. 2- devolopment of complications: recurrent UTI from BPH - recurrent gross hematuria from BPH – bladder stones from BPH – renal impairment & hydroureteronephrosis from BPH – refractory urine retention ( failure of cathetre removal for at least one attempt.

Retropubic prostatectomy

Transvesical prostatectomy

Transurethral resection of the prostate - TURP

Transurethral resection of the prostate TURP 95% of simple prostatectomies can be done endoscopically. Most of these procedures involve the use of a spinal anaesthesia and require a 1- to 2-day hospital stay. Risks of TURP include retrograde ejaculation (75%), impotence (5–10%), and incontinence (<1%).

Complications include: bleeding,UTI, urethral stricture or bladder neck contracture, perforation of the prostate capsule with extravasation, and if severe, TUR syndrome resulting from a hypervolemic, hyponatremic state due to absorption of the hypotonic irrigating solution. Clinical manifestations of the TUR syndrome include nausea, vomiting, confusion, hypertension, bradycardia, and visual disturbances.( Mortality Rate 40-50 %)